FDA rejects Biocon Biologics BLA for Insulin-R product

TAGS

Biocon Limited, an Indian biopharma company, said that its subsidiary Biocon Biologics has been issued a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the biologics license application (BLA) for the Insulin-R product.

The FDA has rejected the BLA seeking more data to support its submission and an expectation of satisfactory implementing a corrective and preventive actions (CAPA) plan regarding the pre-approval inspection of Biocon Limited’s facilities in August 22.

FDA rejects Biocon Biologics BLA for Insulin-R product

FDA rejects Biocon Biologics BLA for Insulin-R product. Photo courtesy of Biocon.

A company spokesperson of Biocon Biologics said: “We are in the process of comprehensively addressing the CRL.”

See also  Hero MotoCorp Q1 FY’24 revenue rises to Rs 8,767cr amidst favorable economic trends

In late 2022, Biocon Biologics completed the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris.

CATEGORIES
TAGS
Share This